Q4 2016 EPS Estimates for Zeltiq Aesthetics Inc. (ZLTQ) Decreased by Analyst
Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) – Stock analysts at Northcoast Research cut their Q4 2016 earnings estimates for shares of Zeltiq Aesthetics in a research note issued to investors on Friday. Northcoast Research analyst E. Snyder now expects that the brokerage will earn $0.18 per share for the quarter, down from their prior forecast of $0.19. Northcoast Research currently has a “Buy” rating on the stock. Northcoast Research also issued estimates for Zeltiq Aesthetics’ Q2 2017 earnings at $0.21 EPS, Q3 2017 earnings at $0.25 EPS, Q4 2017 earnings at $0.28 EPS and FY2017 earnings at $0.60 EPS.
Zeltiq Aesthetics (NASDAQ:ZLTQ) last issued its quarterly earnings data on Wednesday, November 9th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.08 by $0.04. Zeltiq Aesthetics had a negative return on equity of 6.45% and a net margin of 9.48%. The business had revenue of $95.20 million for the quarter, compared to the consensus estimate of $90.84 million. During the same period in the prior year, the business earned $0.05 earnings per share. The business’s revenue was up 55.6% on a year-over-year basis.
ZLTQ has been the topic of several other reports. Maxim Group lifted their price target on Zeltiq Aesthetics from $40.00 to $48.00 and gave the company a “buy” rating in a research report on Tuesday, August 9th. Stifel Nicolaus lifted their target price on Zeltiq Aesthetics from $38.00 to $52.00 and gave the stock a “buy” rating in a report on Wednesday, September 21st. Zacks Investment Research upgraded Zeltiq Aesthetics from a “sell” rating to a “hold” rating in a report on Saturday, July 23rd. Brean Capital restated a “buy” rating on shares of Zeltiq Aesthetics in a report on Monday, October 24th. Finally, Leerink Swann restated an “outperform” rating and issued a $48.00 target price on shares of Zeltiq Aesthetics in a report on Thursday, August 25th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $42.78.
Shares of Zeltiq Aesthetics (NASDAQ:ZLTQ) opened at 39.63 on Monday. The stock has a 50 day moving average price of $37.66 and a 200 day moving average price of $33.50. The stock has a market capitalization of $1.58 billion, a P/E ratio of 51.14 and a beta of 0.89. Zeltiq Aesthetics has a 12 month low of $18.41 and a 12 month high of $41.48.
In related news, insider Keith J. Sullivan sold 8,000 shares of Zeltiq Aesthetics stock in a transaction on Friday, November 4th. The stock was sold at an average price of $33.01, for a total transaction of $264,080.00. Following the completion of the sale, the insider now owns 82,023 shares of the company’s stock, valued at $2,707,579.23. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Sergio Garcia sold 20,000 shares of Zeltiq Aesthetics stock in a transaction on Monday, October 17th. The shares were sold at an average price of $39.08, for a total value of $781,600.00. Following the sale, the vice president now directly owns 86,241 shares of the company’s stock, valued at approximately $3,370,298.28. The disclosure for this sale can be found here. Corporate insiders own 15.60% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the stock. Symmetry Peak Management LLC purchased a new stake in Zeltiq Aesthetics during the third quarter worth about $294,000. D. E. Shaw & Co. Inc. boosted its stake in shares of Zeltiq Aesthetics by 102.2% in the third quarter. D. E. Shaw & Co. Inc. now owns 54,507 shares of the company’s stock worth $2,138,000 after buying an additional 27,551 shares in the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Zeltiq Aesthetics during the third quarter worth $945,000. Two Sigma Advisers LP bought a new stake in shares of Zeltiq Aesthetics during the third quarter worth $1,664,000. Finally, United Services Automobile Association boosted its stake in shares of Zeltiq Aesthetics by 13.9% in the third quarter. United Services Automobile Association now owns 146,599 shares of the company’s stock worth $5,750,000 after buying an additional 17,900 shares in the last quarter.
About Zeltiq Aesthetics
ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.
Receive News & Stock Ratings for Zeltiq Aesthetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc. and related stocks with our FREE daily email newsletter.